Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
June 16, 2017
Spago Nanomedical

SpagoPix product patent approved in Japan

Spago Nanomedical announce today that the Japanese patent authorities has decided to approve the company's patent application comprising the nanoparticles that are the foundation of the SpagoPix project.

SpagoPix product patent approved in Japan

Spago Nanomedical announce today that the Japanese patent authorities has decided to approve the company's patent application comprising the nanoparticles that are the foundation of the SpagoPix project.

Spago Nanomedical announce today that the Japanese patent authorities has decided to approve the company's patent application comprising the nanoparticles that are the foundation of the SpagoPix project.

The approved patent (Manganese comprising nanostructures, 2014-531227) means that Spago Nanomedical gains strategic market protection for SpagoPix on the world's third largest market for MRI contrast agents. The patent include the company´s unique nanoparticles which will now gain market exclusivity in Japan until at least 2032.

The application for product protection is submitted in all substantial markets and patent has previously been granted in e.g. USA.

Late 2016 the product candidate SN132D was appointed in the SpagoPix project and production of material for regulatory tox- and safety studies is underway. The aim is work with a well-established CRO for initiation of the program as soon as possible.

For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, mats.hansen@spagonanomedical.se.

Last updated:
June 16, 2017

Spago Nanomedical

Spago Nanomedical AB is a Swedish company performing research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 22
SE-223 63 Lund
Sweden

Send us mail

Spago Nanomedical announce today that the Japanese patent authorities has decided to approve the company's patent application comprising the nanoparticles that are the foundation of the SpagoPix project.

The approved patent (Manganese comprising nanostructures, 2014-531227) means that Spago Nanomedical gains strategic market protection for SpagoPix on the world's third largest market for MRI contrast agents. The patent include the company´s unique nanoparticles which will now gain market exclusivity in Japan until at least 2032.

The application for product protection is submitted in all substantial markets and patent has previously been granted in e.g. USA.

Late 2016 the product candidate SN132D was appointed in the SpagoPix project and production of material for regulatory tox- and safety studies is underway. The aim is work with a well-established CRO for initiation of the program as soon as possible.

For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, mats.hansen@spagonanomedical.se.

Last updated:
June 16, 2017

Spago Nanomedical

Spago Nanomedical AB is a Swedish company performing research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials

Click here to read more about us!
Get in touch with us!
Visit us

Scheelevägen 22
SE-223 63 Lund
Sweden

Send us mail